SOLO-3 Phase 3 trial

June 5, 2019June 5, 2019

Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free survival ... Read more

January 18, 2019

Lynparza Improves Response Rate in Relapsed BRCA-mutated Advanced OC Patients

News

Results of a Phase 3 clinical trial show that Lynparza (olaparib) tablets met the primary goal of significantly improving the objective response rate, which is the percentage of patients whose cancer shrinks or ... Read more